419 related articles for article (PubMed ID: 17762903)
21. Drug insight: rituximab in renal disease and transplantation.
Salama AD; Pusey CD
Nat Clin Pract Nephrol; 2006 Apr; 2(4):221-30. PubMed ID: 16932428
[TBL] [Abstract][Full Text] [Related]
22. CD20-depleting therapy in autoimmune diseases: from basic research to the clinic.
Perosa F; Prete M; Racanelli V; Dammacco F
J Intern Med; 2010 Mar; 267(3):260-77. PubMed ID: 20201920
[TBL] [Abstract][Full Text] [Related]
23. Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects.
Ratanatharathorn V; Pavletic S; Uberti JP
Cancer Treat Rev; 2009 Dec; 35(8):653-61. PubMed ID: 19682801
[TBL] [Abstract][Full Text] [Related]
24. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy.
Zhou X; Hu W; Qin X
Oncologist; 2008 Sep; 13(9):954-66. PubMed ID: 18779537
[TBL] [Abstract][Full Text] [Related]
25. A review of the current use of rituximab in autoimmune diseases.
Gürcan HM; Keskin DB; Stern JN; Nitzberg MA; Shekhani H; Ahmed AR
Int Immunopharmacol; 2009 Jan; 9(1):10-25. PubMed ID: 19000786
[TBL] [Abstract][Full Text] [Related]
26. Rituximab and its use in autoimmune bullous disorders.
Daniel BS; Murrell DF; Joly P
Immunol Allergy Clin North Am; 2012 May; 32(2):331-7, viii. PubMed ID: 22560146
[TBL] [Abstract][Full Text] [Related]
27. [Rationale and clinical evidence for the use of rituximab in glomerular diseases].
Mani LY; Vogt B; Burnier M; Golshayan D
Rev Med Suisse; 2011 Apr; 7(290):819-24. PubMed ID: 21595313
[TBL] [Abstract][Full Text] [Related]
28. [Biological dermatologic agents. The Danish Society of Dermatology].
Iversen L; Kragballe K;
Ugeskr Laeger; 2007 Mar; 169(12):1100. PubMed ID: 17394811
[No Abstract] [Full Text] [Related]
29. Progression of classic Kaposi's sarcoma with rituximab.
Clifford KS; Demierre MF
J Am Acad Dermatol; 2005 Jul; 53(1):155-7. PubMed ID: 15965441
[TBL] [Abstract][Full Text] [Related]
30. B cell depletion in autoimmune disease.
Gorman C; Leandro M; Isenberg D
Arthritis Res Ther; 2003; 5 Suppl 4(Suppl 4):S17-21. PubMed ID: 15180893
[TBL] [Abstract][Full Text] [Related]
31. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.
Maloney DG; Grillo-López AJ; White CA; Bodkin D; Schilder RJ; Neidhart JA; Janakiraman N; Foon KA; Liles TM; Dallaire BK; Wey K; Royston I; Davis T; Levy R
Blood; 1997 Sep; 90(6):2188-95. PubMed ID: 9310469
[TBL] [Abstract][Full Text] [Related]
32. CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells.
Hayden-Ledbetter MS; Cerveny CG; Espling E; Brady WA; Grosmaire LS; Tan P; Bader R; Slater S; Nilsson CA; Barone DS; Simon A; Bradley C; Thompson PA; Wahl AF; Ledbetter JA
Clin Cancer Res; 2009 Apr; 15(8):2739-46. PubMed ID: 19351771
[TBL] [Abstract][Full Text] [Related]
33. B cell depletion therapy for new-onset opsoclonus-myoclonus.
Pranzatelli MR; Tate ED; Swan JA; Travelstead AL; Colliver JA; Verhulst SJ; Crosley CJ; Graf WD; Joseph SA; Kelfer HM; Raju GP
Mov Disord; 2010 Jan; 25(2):238-42. PubMed ID: 20063398
[TBL] [Abstract][Full Text] [Related]
34. Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab.
Fleischmann RM
Semin Arthritis Rheum; 2009 Feb; 38(4):265-80. PubMed ID: 18336874
[TBL] [Abstract][Full Text] [Related]
35. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus.
Albert D; Dunham J; Khan S; Stansberry J; Kolasinski S; Tsai D; Pullman-Mooar S; Barnack F; Striebich C; Looney RJ; Prak ET; Kimberly R; Zhang Y; Eisenberg R
Ann Rheum Dis; 2008 Dec; 67(12):1724-31. PubMed ID: 18250115
[TBL] [Abstract][Full Text] [Related]
36. Treatment of adult inflammatory myositis with rituximab: an emerging therapy for refractory patients.
Majmudar S; Hall HA; Zimmermann B
J Clin Rheumatol; 2009 Oct; 15(7):338-40. PubMed ID: 20009968
[TBL] [Abstract][Full Text] [Related]
37. Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma.
Biehn SE; Kirk D; Rivera MP; Martinez AE; Khandani AH; Orlowski RZ
Hematol Oncol; 2006 Dec; 24(4):234-7. PubMed ID: 16948177
[TBL] [Abstract][Full Text] [Related]
38. Rituximab for the treatment of post-bone marrow transplantation refractory hemolytic anemia in a child with Omenn's syndrome.
Silvana B; Antonella LM; Basilia P; Trombetta D; Saija A; Salpietro C
Pediatr Transplant; 2007 Aug; 11(5):552-6. PubMed ID: 17631027
[TBL] [Abstract][Full Text] [Related]
39. Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells.
Liossis SN; Sfikakis PP
Clin Immunol; 2008 Jun; 127(3):280-5. PubMed ID: 18337174
[TBL] [Abstract][Full Text] [Related]
40. Development of psoriasis after B cell depletion with rituximab.
Dass S; Vital EM; Emery P
Arthritis Rheum; 2007 Aug; 56(8):2715-8. PubMed ID: 17665440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
